Movement Alert｜HANSOH PHARMA Falls 3.09% in Regular Trading, Pharmaceuticals Sector Broadly Under Pressure

Market Focus10:06

On September 24, HANSOH PHARMA fell 3.09% in regular trading, trading at HKD 33.86 per share, with turnover of HKD 41.39 million. The decline came amid broad-based selling pressure across the pharmaceuticals sector, despite a string of positive company-specific catalysts in recent weeks.

The wider pharmaceutical industry saw widespread weakness during the session. Among major sector peers, CSPC Pharma fell 1.97%, China Biopharmaceutical dropped 2.55%, Asymchem declined 4.58%, and Hengrui Pharma slid 2.80%, while HUTCHMED edged up 0.27%. The sector-wide downdraft overshadowed HANSOH PHARMA's recent positive developments, including its HS-20093 osteosarcoma indication gaining NMPA priority review on September 22, and the Phase 3 success of its TYK2 inhibitor HS-10374 for moderate-to-severe plaque psoriasis announced on September 21. Multiple investment banks have maintained buy ratings on the stock, with target prices ranging from HKD 43.70 to HKD 52.70, suggesting significant upside from current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180563170?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180563170","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Falls 3.09% in Regular Trading, Pharmaceuticals Sector Broadly Under Pressure","media":"Market Focus","content":"<p><p>On September 24, HANSOH PHARMA fell 3.09% in regular trading, trading at HKD 33.86 per share, with turnover of HKD 41.39 million. The decline came amid broad-based selling pressure across the pharmaceuticals sector, despite a string of positive company-specific catalysts in recent weeks.</p><p>The wider pharmaceutical industry saw widespread weakness during the session. Among major sector peers, CSPC Pharma fell 1.97%, China Biopharmaceutical dropped 2.55%, Asymchem declined 4.58%, and Hengrui Pharma slid 2.80%, while HUTCHMED edged up 0.27%. The sector-wide downdraft overshadowed HANSOH PHARMA's recent positive developments, including its HS-20093 osteosarcoma indication gaining NMPA priority review on September 22, and the Phase 3 success of its TYK2 inhibitor HS-10374 for moderate-to-severe plaque psoriasis announced on September 21. Multiple investment banks have maintained buy ratings on the stock, with target prices ranging from HKD 43.70 to HKD 52.70, suggesting significant upside from current levels.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Falls 3.09% in Regular Trading, Pharmaceuticals Sector Broadly Under Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Falls 3.09% in Regular Trading, Pharmaceuticals Sector Broadly Under Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, HANSOH PHARMA fell 3.09% in regular trading, trading at HKD 33.86 per share, with turnover of HKD 41.39 million. The decline came amid broad-based selling pressure across the pharmaceuticals sector, despite a string of positive company-specific catalysts in recent weeks.</p><p>The wider pharmaceutical industry saw widespread weakness during the session. Among major sector peers, CSPC Pharma fell 1.97%, China Biopharmaceutical dropped 2.55%, Asymchem declined 4.58%, and Hengrui Pharma slid 2.80%, while HUTCHMED edged up 0.27%. The sector-wide downdraft overshadowed HANSOH PHARMA's recent positive developments, including its HS-20093 osteosarcoma indication gaining NMPA priority review on September 22, and the Phase 3 success of its TYK2 inhibitor HS-10374 for moderate-to-severe plaque psoriasis announced on September 21. Multiple investment banks have maintained buy ratings on the stock, with target prices ranging from HKD 43.70 to HKD 52.70, suggesting significant upside from current levels.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1180563170","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180563170","pubTimestamp":1790215615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, HANSOH PHARMA fell 3.09% in regular trading, trading at HKD 33.86 per share, with turnover of HKD 41.39 million. The decline came amid broad-based selling pressure across the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势警报|豪森制药常规交易下跌3.09%，医药板块普遍承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On September 24, HANSOH PHARMA fell 3.09% in regular trading, trading at HKD 33.86 per share, with turnover of HKD 41.39 million. The decline came amid broad-based selling pressure across the pharmaceuticals sector, despite a string of positive company-specific catalysts in recent weeks.The wider pharmaceutical industry saw widespread weakness during the session. Among major sector peers, CSPC Pharma fell 1.97%, China Biopharmaceutical dropped 2.55%, Asymchem declined 4.58%, and Hengrui Pharma slid 2.80%, while HUTCHMED edged up 0.27%. The sector-wide downdraft overshadowed HANSOH PHARMA's recent positive developments, including its HS-20093 osteosarcoma indication gaining NMPA priority review on September 22, and the Phase 3 success of its TYK2 inhibitor HS-10374 for moderate-to-severe plaque psoriasis announced on September 21. Multiple investment banks have maintained buy ratings on the stock, with target prices ranging from HKD 43.70 to HKD 52.70, suggesting significant upside from current levels.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180563170","isCrawlerRequest":true}